To gain a better understanding, we investigated the comprehensive cellular consequences of MX treatment in HR-deficient BRCA1-mutant UWB1.289 (BRCA1−) and HR-proficient (BRCA1+) UWB1.289 ovarian cancer cells using quantitative shotgun proteomics. This evidence concerns the gene BRCA1 and ovarian cancer.